Studies evaluating our lead veterinary immunotherapy candidate, MIE-201, in canine companion animals with multiple tumor types have consistently demonstrated immune activation, antitumor activity, increased survival and no signs of toxicity or adverse events. We plan to expand on these promising data by advancing MIE-201 into larger canine efficacy and safety field studies. Our veterinary management team is currently coordinating with regulatory authorities to develop an efficient and effective strategy to potentially advance MIE-201 toward conditional approval for canine cancers.